NovaDx, Abbott deal

NVN granted Abbott a renewable one-year option to acquire a non-exclusive worldwide license to NVN's diagnostic technology and assays for detecting multiple forms of arthritis. The deal includes access to NVN's Chondrex (YKL-40) arthritis blood test and an additional arthritis marker to be identified. ...